查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530824

2030 年疫苗市場預測：按疫苗類型、疾病類型、給藥途徑、年齡層、最終用戶和地區進行全球分析

Vaccines Market Forecasts to 2030 - Global Analysis By Vaccine Type, Disease Type, Route of Administration, Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2024年全球疫苗市場規模為802.4億美元，預計2030年將達到973.8億美元，預測期內複合年成長率為6.2%。

疫苗是生物製藥，旨在提供針對特定疾病的免疫力。疫苗含有病原體的弱化或惰性部分，例如蛋白質或遺傳物質，以刺激免疫系統識別和對抗病原體。透過觸發免疫反應，疫苗可以幫助發育記憶細胞，如果將來接觸到病原體，這些細胞可以識別並對抗病原體。這種積極主動的方法有助於預防感染疾病及其併發症，為個人和公共衛生做出貢獻。

據聯合國衛生機構稱，截至 2021 年 9 月，只有 3% 的人至少接種了一劑 COVID-19 疫苗，而高所得國家的比例為 60.18%。

感染疾病增加

隨著新發和重新出現的感染疾病感染疾病更加普遍，各國政府和醫療機構正在優先考慮疫苗接種，以保護公眾健康並減輕疫情爆發。這種不斷成長的需求將推動對疫苗研究、開發和生產的投資。此外，隨著疾病爆發，公眾意識和緊迫感增強，推動疫苗接種率提高並擴大市場機會。因此，製藥公司和研究機構熱衷於創新和擴展疫苗解決方案，進一步推動市場成長。

副作用和安全問題

疫苗的不良反應和安全問題源自於個別反應、潛在副作用或罕見併發症。這些問題可能是由疫苗成分、生產過程或潛在的健康狀況引起的。這種擔憂可能會導致公眾懷疑並減少疫苗的使用。負面新聞報導和錯誤訊息可能會進一步加劇恐懼並影響整體疫苗接種率。信任和需求的下降可能會阻礙市場成長。

增加政府措施和資金

各國政府已撥出大量資金支持疫苗研發，促進創新疫苗的開發和對新興疾病的快速反應。公共資金也有助於降低疫苗生產成本，並使疫苗更容易獲得，特別是在服務不足的地區。此外，政府主導的免疫計劃提高了疫苗接種率，改善了公共衛生，並推動了市場需求。這些努力將加強疫苗供應鏈，促進全球衛生安全，進而推動整體市場成長。

開發和製造成本高

開發和生產疫苗的高成本是由於廣泛的研究、臨床試驗和嚴格的監管要求所造成的。製造需要複雜的製程、品管和專用設備，這進一步增加了成本。因此，高成本可能會限制疫苗的供應、阻礙廣泛的免疫接種以及限制對新疫苗開發和創新的投資，從而減緩市場成長。

COVID-19 的影響

COVID-19大流行加速了疫苗的開發和生產，大大提振了疫苗市場，凸顯了快速反應在公共衛生中的關鍵作用。這場危機引發了前所未有的全球合作和資金籌措，導致了 COVID-19 疫苗的快速生產和分配。這段經歷增加了人們對疫苗研究和基礎設施的興趣和投資。然而，它也暴露了疫苗分配不公平和公眾猶豫不決等挑戰。整體而言，疫情凸顯了疫苗的重要性，刺激了產業進步，並影響了未來的市場動態。

預計兒科領域在預測期內將是最大的。

預計兒科業務將出現良好成長。兒科疫苗是專為兒童設計的免疫接種，旨在預防常見和嚴重的疾病。這些疫苗對於預防麻疹、德國麻疹、德國麻疹和百日咳等疾病至關重要。早期接種疫苗可以幫助兒童在接觸這些病原體之前建立對這些病原體的免疫力。免疫接種計劃經過精心設計，以確保及時預防，有助於整體公共衛生並減少疾病發病率。

研究機構領域預計在預測期內複合年成長率最高

預計研究機構部門在預測期內將出現最高的複合年成長率。研究實驗室使用疫苗來提高對疫苗的科學認知並開發新的免疫技術。研究機構正在對疫苗功效、安全性和創新管理方法進行研究。研究機構正在進行疫苗功效、安全性和創新遞送方法的研究，研究新型疫苗平台並探索疾病預防的新目標。研究主導的疫苗開發旨在解決新興和現有的疾病、改善公共衛生結果並推動醫學發展。

比最大的地區

由於醫療保健投資增加、疾病發病率上升和免疫計劃擴大，亞太疫苗市場正在經歷快速成長。由於人口密度高和新出現疾病的威脅，各國政府正在優先考慮疫苗的可用性和可負擔性。疫苗技術的創新和強力的公共衛生措施正在進一步刺激市場擴張。該地區已成為疫苗開發和分配的關鍵地區，反映出不斷成長的醫療保健需求。

複合年成長率最高的地區：

由於先進的醫療基礎設施、高疫苗接種率以及對研發的大量投資，北美疫苗市場仍然強勁。該地區受益於政府的大力支持，包括資金和公共衛生舉措，以及公眾對疫苗益處的高度認知。持續的技術創新和新疫苗的快速開發也正在推動市場。總體而言，北美持續引領全球疫苗市場。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球疫苗市場：依疫苗類型

  • 去活化疫苗
  • 減毒活疫苗
  • 結合疫苗
  • mRNA（信使核糖核酸）疫苗
  • DNA（去氧核糖核酸）疫苗
  • 類毒素疫苗
  • 其他疫苗類型

第6章全球疫苗市場：依疾病類型

  • 感染疾病
  • 癌症疫苗
  • 自體免疫疾病
  • 旅行疫苗
  • 其他疾病類型

第7章 全球疫苗市場：依給藥途徑

  • 注射
  • 口服
  • 鼻腔
  • 經皮的

第8章全球疫苗市場：依年齡層別

  • 小兒科
  • 成人
  • 老年病

第9章 全球疫苗市場：依最終用戶分類

  • 醫院
  • 藥局
  • 公共衛生機構
  • 研究所
  • 其他最終用戶

第10章全球疫苗市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • Pfizer Inc.
  • Moderna Inc.
  • Johnson & Johnson
  • Sanofi Pasteur
  • GlaxoSmithKline（GSK）
  • AstraZeneca
  • Novartis AG
  • Merck & Co., Inc.
  • Bavarian Nordic
  • BioNTech SE
  • Serum Institute of India
  • CureVac NV
  • Abbott Laboratories
  • Clover Biopharmaceuticals
  • Inovio Pharmaceuticals
  • Indian Immunologicals Limited（IIL）
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sinovac Biotech
Product Code: SMRC26936

According to Stratistics MRC, the Global Vaccines Market is accounted for $80.24 billion in 2024 and is expected to reach $97.38 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Vaccines are biological preparations designed to provide immunity against specific diseases. They contain weakened or inactive parts of a pathogen, such as proteins or genetic material, which stimulate the immune system to recognize and fight the pathogen. By triggering an immune response, vaccines help the body develop memory cells that can recognize and combat the pathogen if exposed in the future. This proactive approach helps prevent infections and their potential complications, contributing to individual and public health.

According to the United Nations Health Agency, as of September 2021, only 3% of people had been vaccinated with at least one dose of the covid -19 vaccine, compared to 60.18% in high-income countries.

Market Dynamics:

Driver:

Rising incidence of infectious diseases

As new and re-emerging diseases spread, both governments and healthcare organizations prioritize vaccination to protect public health and mitigate outbreaks. This heightened need drives investments in vaccine research, development, and production. Additionally, increased disease prevalence raises public awareness and urgency, encouraging higher vaccination rates and expanding market opportunities. Consequently, pharmaceutical companies and research institutions are motivated to innovate and scale up vaccine solutions, further fueling market growth.

Restraint:

Adverse reactions and safety concerns

Adverse reactions and safety concerns in vaccines arise from individual responses, potential side effects, or rare complications. These issues can stem from vaccine components, manufacturing processes, or underlying health conditions. Such concerns may lead to public skepticism and decreased vaccine uptake. Negative reports and misinformation can further amplify fears, impacting overall vaccination rates. This reduced trust and lower demand can hamper market growth.

Opportunity:

Mounting government initiatives and funding

Governments allocate substantial resources to support vaccine R&D, facilitating the creation of innovative vaccines and faster response to emerging diseases. Public funding also helps reduce the cost of vaccine production and makes vaccines more accessible, particularly in underserved regions. Additionally, government-led immunization programs increase vaccination rates, boost public health, and drive market demand. These efforts collectively strengthen the vaccine supply chain and promote global health security, fostering overall market growth.

Threat:

High development and production costs

High development and production costs in vaccines arise from extensive research, clinical trials, and stringent regulatory requirements. Manufacturing involves complex processes, quality control, and specialized equipment, further increasing expenses. Consequently, high costs can slow market growth by restricting vaccine availability, impeding widespread immunization efforts, and limiting investments in new vaccine development and innovation.

Covid-19 Impact

The covid-19 pandemic significantly propelled the vaccines market by accelerating vaccine development and production, highlighting the critical role of rapid response in public health. The crisis led to unprecedented global collaboration and funding, resulting in the swift creation and distribution of covid-19 vaccines. This experience boosted interest and investment in vaccine research and infrastructure. However, it also exposed challenges such as vaccine distribution inequities and public hesitancy. Overall, the pandemic underscored the importance of vaccines and spurred advancements in the industry, influencing future market dynamics.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Pediatric vaccines are immunizations specifically designed for children to protect against common and serious diseases. These vaccines are crucial for preventing illnesses such as measles, mumps, rubella, and whooping cough. Early vaccination helps establish immunity before children are exposed to these pathogens. Immunization schedules are carefully designed to ensure timely protection, contributing to overall public health and reducing disease outbreaks.

The research institutions segment is expected to have the highest CAGR during the forecast period

The research institutions segment is anticipated to witness the highest CAGR growth during the forecast period. In research institutions, vaccines are used to advance scientific understanding and develop new immunization technologies. These institutions conduct studies on vaccine efficacy, safety, and innovative delivery methods. They explore novel vaccine platforms, and investigate new targets for disease prevention. Research-driven vaccine development aims to address emerging and existing diseases, improving public health outcomes and advancing medical science.

Region with largest share:

The vaccines market in the Asia-Pacific region is experiencing rapid growth due to increasing healthcare investments, rising disease incidence, and expanding immunization programs. Governments are prioritizing vaccine accessibility and affordability, driven by high population density and emerging disease threats. Innovations in vaccine technology and robust public health initiatives further stimulate market expansion. The region remains a key area for vaccine development and distribution, reflecting its growing healthcare needs.

Region with highest CAGR:

The vaccines market in North America is robust, driven by advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development. The region benefits from strong government support, including funding and public health initiatives, as well as a high level of public awareness about vaccine benefits. The market is also fuelled by ongoing innovation and the rapid development of new vaccines. Overall, North America remains a leading player in the global vaccine market.

Key players in the market

Some of the key players profiled in the Vaccines Market include Pfizer Inc., Moderna Inc., Johnson & Johnson, Sanofi Pasteur, GlaxoSmithKline (GSK), AstraZeneca, Novartis AG, Merck & Co., Inc., Bavarian Nordic, BioNTech SE, Serum Institute of India, CureVac N.V., Abbott Laboratories, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Indian Immunologicals Limited (IIL), Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Sinovac Biotech.

Key Developments:

In January 2024, Indian Immunologicals Ltd (IIL), a wholly-owned subsidiary of National Dairy Development Board (NDDB), launched India's 'first' indigenously developed Hepatitis A vaccine. Havisure is expected to play a key role to protect against the Hepatitis A virus, which primarily affects the liver. The vaccine is effective in preventing the disease and is recommended for children in routine immunisation.

In November 2022, Pfizer Inc. and BioNTech SE have advanced a promising vaccine candidate into clinical trials. Their new mRNA-based combination vaccine aims to tackle two significant respiratory illnesses: influenza and COVID-19. This vaccine, currently in Phase 1 trials, represents a notable step forward in public health innovation.

Vaccine Types Covered:

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • mRNA (messenger Ribonucleic Acid) Vaccines
  • DNA (Deoxyribonucleic Acid) Vaccines
  • Toxoid Vaccines
  • Other Vaccine Types

Disease Types Covered:

  • Infectious Diseases
  • Cancer Vaccines
  • Autoimmune Diseases
  • Travel-Related Vaccines
  • Other Disease Types

Route of Administrations Covered:

  • Injectable
  • Oral
  • Nasal
  • Transdermal

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

End Users Covered:

  • Hospitals
  • Pharmacies
  • Public Health Organizations
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccines Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Inactivated Vaccines
  • 5.3 Live Attenuated Vaccines
  • 5.4 Conjugate Vaccines
  • 5.5 mRNA (messenger Ribonucleic Acid) Vaccines
  • 5.6 DNA (Deoxyribonucleic Acid) Vaccines
  • 5.7 Toxoid Vaccines
  • 5.8 Other Vaccine Types

6 Global Vaccines Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cancer Vaccines
  • 6.4 Autoimmune Diseases
  • 6.5 Travel-Related Vaccines
  • 6.6 Other Disease Types

7 Global Vaccines Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Injectable
  • 7.3 Oral
  • 7.4 Nasal
  • 7.5 Transdermal

8 Global Vaccines Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Adult
  • 8.4 Geriatric

9 Global Vaccines Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmacies
  • 9.4 Public Health Organizations
  • 9.5 Research Institutions
  • 9.6 Other End Users

10 Global Vaccines Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Moderna Inc.
  • 12.3 Johnson & Johnson
  • 12.4 Sanofi Pasteur
  • 12.5 GlaxoSmithKline (GSK)
  • 12.6 AstraZeneca
  • 12.7 Novartis AG
  • 12.8 Merck & Co., Inc.
  • 12.9 Bavarian Nordic
  • 12.10 BioNTech SE
  • 12.11 Serum Institute of India
  • 12.12 CureVac N.V.
  • 12.13 Abbott Laboratories
  • 12.14 Clover Biopharmaceuticals
  • 12.15 Inovio Pharmaceuticals
  • 12.16 Indian Immunologicals Limited (IIL)
  • 12.17 Bayer AG
  • 12.18 Takeda Pharmaceutical Company Limited
  • 12.19 Eli Lilly and Company
  • 12.20 Sinovac Biotech

List of Tables

  • Table 1 Global Vaccines Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Vaccines Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 3 Global Vaccines Market Outlook, By Inactivated Vaccines (2022-2030) ($MN)
  • Table 4 Global Vaccines Market Outlook, By Live Attenuated Vaccines (2022-2030) ($MN)
  • Table 5 Global Vaccines Market Outlook, By Conjugate Vaccines (2022-2030) ($MN)
  • Table 6 Global Vaccines Market Outlook, By mRNA (messenger Ribonucleic Acid) Vaccines (2022-2030) ($MN)
  • Table 7 Global Vaccines Market Outlook, By DNA (Deoxyribonucleic Acid) Vaccines (2022-2030) ($MN)
  • Table 8 Global Vaccines Market Outlook, By Toxoid Vaccines (2022-2030) ($MN)
  • Table 9 Global Vaccines Market Outlook, By Other Vaccine Types (2022-2030) ($MN)
  • Table 10 Global Vaccines Market Outlook, By Disease Type (2022-2030) ($MN)
  • Table 11 Global Vaccines Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 12 Global Vaccines Market Outlook, By Cancer Vaccines (2022-2030) ($MN)
  • Table 13 Global Vaccines Market Outlook, By Autoimmune Diseases (2022-2030) ($MN)
  • Table 14 Global Vaccines Market Outlook, By Travel-Related Vaccines (2022-2030) ($MN)
  • Table 15 Global Vaccines Market Outlook, By Other Disease Types (2022-2030) ($MN)
  • Table 16 Global Vaccines Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 17 Global Vaccines Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 18 Global Vaccines Market Outlook, By Oral (2022-2030) ($MN)
  • Table 19 Global Vaccines Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 20 Global Vaccines Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 21 Global Vaccines Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 22 Global Vaccines Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 23 Global Vaccines Market Outlook, By Adult (2022-2030) ($MN)
  • Table 24 Global Vaccines Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 25 Global Vaccines Market Outlook, By End User (2022-2030) ($MN)
  • Table 26 Global Vaccines Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 27 Global Vaccines Market Outlook, By Pharmacies (2022-2030) ($MN)
  • Table 28 Global Vaccines Market Outlook, By Public Health Organizations (2022-2030) ($MN)
  • Table 29 Global Vaccines Market Outlook, By Research Institutions (2022-2030) ($MN)
  • Table 30 Global Vaccines Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.